Tyra CEO acquires 1,463 shares via ESPP grant

Tyra Biosciences President and CEO Harris Todd increased his direct holdings through a compensation-related share acquisition.

Accepted by SEC EDGAR 03/17/2026 - 04:54 PM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

Tyra Biosciences President and CEO Harris Todd increased his direct holdings through a compensation-related share acquisition. On March 13, 2026, he acquired 1,463 shares of Tyra Biosciences common stock at $9.129 per share under the company’s 2021 Employee Stock Purchase Plan.

After this transaction, Todd directly owns 1,358,631 common shares. This was a grant/award-type acquisition under an employee plan, not an open-market purchase, and represents a small addition relative to his existing stake.

Insider Trade Summary

Grant/Award: 1,463 shares

Grant/Award 1 txn

Insider Harris Todd

Role President and CEO

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	1,463	$9.129	$13K

Holdings After Transaction: Common Stock — 1,358,631 shares (Direct)

Holdings Before and After: Common Stock, 1,357,168 to 1,358,631 shares (Direct)

Footnotes (1)

1. F1. These shares were acquired under the Issuer's 2021 Employee Stock Purchase Plan.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Tyra Biosciences (TYRA) CEO Harris Todd report in this Form 4?

Harris Todd reported acquiring 1,463 shares of Tyra Biosciences common stock. The shares were obtained as a compensation-related award under the company’s 2021 Employee Stock Purchase Plan, rather than through an open-market purchase, and modestly increased his existing direct ownership stake.

How many Tyra Biosciences (TYRA) shares did the CEO acquire and at what price?

Harris Todd acquired 1,463 shares of Tyra Biosciences common stock at a price of $9.129 per share. The transaction is recorded as a grant or award acquisition, reflecting shares obtained through an employee stock purchase plan instead of a traditional market trade.

What is Harris Todd’s total Tyra Biosciences (TYRA) share ownership after this transaction?

Following the reported acquisition, Harris Todd directly owns 1,358,631 shares of Tyra Biosciences common stock. This updated total reflects the addition of 1,463 shares obtained through the company’s 2021 Employee Stock Purchase Plan as disclosed in the Form 4 filing.

Was the Tyra Biosciences (TYRA) CEO’s Form 4 transaction an open-market stock purchase?

No, the transaction was not an open-market purchase. The 1,463 shares were acquired under Tyra Biosciences’ 2021 Employee Stock Purchase Plan, categorized as a grant, award, or other acquisition, indicating a compensation-related event rather than a discretionary market buy.

What plan was used for the Tyra Biosciences (TYRA) CEO’s share acquisition?

The shares were acquired under Tyra Biosciences’ 2021 Employee Stock Purchase Plan. This type of plan typically allows employees, including executives, to buy company stock on favorable terms as part of their compensation package, rather than executing standard market trades.

Does this Tyra Biosciences (TYRA) Form 4 show any stock sales by the CEO?

No, the Form 4 does not show any stock sales by Harris Todd. It reports only an acquisition of 1,463 common shares through the 2021 Employee Stock Purchase Plan, increasing his direct holdings to 1,358,631 shares without any dispositions in this filing.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Harris Todd

(Last) (First) (Middle)

C/O TYRA BIOSCIENCES, INC.

2656 STATE STREET

(Street)

CARLSBAD CA 92008

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Tyra Biosciences, Inc. [ TYRA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President and CEO

3. Date of Earliest Transaction (Month/Day/Year)
03/13/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/13/2026		A(1)	V	1,463	A	$9.129	1,358,631	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. These shares were acquired under the Issuer's 2021 Employee Stock Purchase Plan.

	/s/ Ali D. Fawaz, Attorney-in-Fact	03/17/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.